Physician profile

Heather Stang

Physician Assistant · Berlin, NJ

NPI 1710455605

$10,609.50

in general payments reported to CMS, 2019-2025

44 companies · $1,559 in 2025

The $1,559 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).

See the full distribution for Physician Assistant

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,126.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $2,313.28 2021-2025
Amgen INC. $1,750.24 2021-2025 Evenity, Repatha, Otezla
Astrazeneca Pharmaceuticals LP $1,572.28 2021-2025 Breztri, Farxiga, Airsupra
Otsuka America Pharmaceutical, INC. $926.09 2021-2025 Rexulti, Abilify Maintena, Abilify Asimtufii
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $810.66 2021-2025 Xifaxan
Alkermes, INC. $544.42 2021-2025 Vivitrol, Vivitrol
Pfizer INC. $398.76 2022-2025
Bayer Healthcare Pharmaceuticals INC. $269.81 2021-2025
Braeburn INC. $255.61 2023-2025 Brixadi
Exact Sciences Corporation $226.62 2023-2025 Cologuard Collection Kit
Kowa Pharmaceuticals America, INC. $214.78 2021-2025 Seglentis, Livalo, Zoryve
Lilly USA, LLC $212.21 2022-2025 Omvoh, Zepbound, Mounjaro
Glaxosmithkline, LLC. $153.89 2021-2025 Shingrix
Lundbeck LLC $118.81 2022-2025 Rexulti
Novartis Pharmaceuticals Corporation $95.39 2021-2022
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $64.43 2021
Amarin Pharma, INC. $59.18 2021
Vanda Pharmaceuticals INC. $53.19 2024-2025 Fanapt
Axsome Therapeutics, INC. $45.13 2024-2025 Auvelity
Biohaven Pharmaceutical Holding Company LTD. $43.84 2022
Biohaven Pharmaceuticals, INC. $41.25 2021
Ardelyx, INC. $40.39 2025 Ibsrela
Madrigal Pharmaceuticals $37.00 2025 Rezdiffra
Merck Sharp & Dohme LLC $31.80 2022-2025 Gardasil 9, Capvaxive
Seqirus USA INC $31.16 2022
Vertos Medical, INC. $27.55 2023 Mild Device Kit
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $20.36 2023
Dexcom, INC. $19.12 2023 Dexcom G6 Transmitter
Corcept Therapeutics $17.61 2025 Korlym
Xeris Pharmaceuticals, INC. $16.90 2024 Keveyis
Corium, LLC $16.87 2024 Azstarys
Indivior INC. $16.31 2025 Sublocade
Tolmar, INC. $15.91 2023
Horizon Therapeutics Plc $14.92 2022
Astellas Pharma US INC $14.88 2021
Phathom Pharmaceuticals, INC. $14.29 2024 Voquezna
Biodelivery Sciences International, INC. $14.02 2021
Takeda Pharmaceuticals U.S.A., INC. $13.96 2024 Trintellix
Sanofi Pasteur INC. $13.88 2022
Radius Health, INC. $13.76 2025
Fidia Pharma USA INC. $13.64 2022
Kaleo, INC. $12.50 2021
Currax Pharmaceuticals LLC $11.69 2021
Opko Pharmaceuticals, LLC $11.11 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Heather Stang

$10,609.50

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $1,559 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/10737499/heather-stang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.